scholarly journals Risk of Ischemic Heart Disease in Patients with Non-alcoholic Fatty Liver Disease

2018 ◽  
Vol 8 (1) ◽  
pp. 41-47
Author(s):  
Mostafa Elkady ◽  
Hatem El-Raouf ◽  
Hany Elkholy ◽  
Badawy Abdul Aziz ◽  
Wael Maklad ◽  
...  
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity

2016 ◽  
Vol 23 (4) ◽  
pp. 2016420
Author(s):  
Nataliya Karpyshyn
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Functional Status ◽  
Fatty Liver Disease ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is atorvastatin which favours better survival outcomes and is essential in the primary and secondary prevention of cardiovascular diseases. Ursodeoxycholic acid is prescribed as an alternative therapy for ischemic heart disease with co-existent non-alcoholic fatty liver disease and obesity to eliminate statin side effects. The use of ursodeoxycholic acid as a hepatoprotector in comprehensive basic treatment contributes to the improvement of the cardiovascular system in patients with ischemic heart disease as well as the increase in treatment efficacy; it improves the functional status of the liver affecting the major pathogenic mechanisms of the disease.The objective of the research was to study the effect of combined hypolipidemic therapy with atorvastatin and ursodeoxycholic acid on the indices of blood lipids, liver transaminase levels, functional status of the liver and the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and obesity.Materials and methods. 20 patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity were examined. They received ursodeoxycholic acid in addition to atorvastatin for four weeks. All the patients underwent clinical tests, visceral ultrasonography, blood lipid test, liver transaminase test and 13C-methacetin breath test.Results. The study revealed a significant decrease in the level of the pro-atherogenic fractions of blood lipids (р<0.01) as well as an improved functional status of the liver due to a significant increase in metabolic capacity of the liver and cumulative dose on the 40th and 120th minutes after ursodeoxycholic acid administration (р<0.01).Conclusions. The use of ursodeoxycholic acid in addition to atorvastatin in patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity makes it possible to avoid the adverse effect of hypolipidemic therapy on the functional status of the liver.

scholarly journals ISCHEMIC HEART DISEASE

2016 ◽  
Vol 23 (09) ◽  
pp. 1057-1059
Author(s):  
Zaigham Rasool Khalid ◽  
Naseem Ahmed ◽  
Farhan Ali Rizvi ◽  
Mirza Ahmad Raza Baig
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Group Versus ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Group I ◽  
Alcoholic Fatty Liver Disease

Objectives: To find the correlation between the non-alcoholic fatty liver disease(NFALD) and ischemic heart disease. Study Design: Retrospective cross-sectional study.Period: May 2014 to Nov 2014. Setting: CPE Institute of Cardiology. Material and methods:One hundred and thirty five participants were incorporated in the study. In Group I; patientswere with NAFLD and in group II; patients were without NAFLD. Data was Analyzed using SPSSV20 software. Results: Mean age in NAFLD group was 52.0+02.6 years and in without NAFLD53.0+1.89 years. There were 73.2 % males in NAFLD group. Incidence of Family history anddiabetes was higher in NAFLD group. The incidence of carotid artery stenosis was 4 (9.7%) inNAFLD group versus 6 (6.3%) in without NAFLD group. we also found a significantly higherincidence of triple vessel and left main stem disease in NAFLD group, it was 34 (80.87%) and3 (7.31%) in NAFLD group versus 9 (9.7%) and 2 (2.12%) in without NALD group respectively.Conclusion: Non-alcoholic Fatty liver Disease has a strong correlation with ischemic heartdisease.

scholarly journals Blood Lipids and Leptin Levels in Patients with Ischemic Heart Disease and Concomitant Non-Alcoholic Fatty Liver Disease after Treatment with Atorvastatin

2016 ◽  
Vol 22 (2) ◽  
pp. 2016212
Author(s):  
Yevgen Sklyarov ◽  
Nataliya Karpyshyn
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Total Cholesterol ◽  
Fatty Liver Disease ◽  
Blood Lipids ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease which is regarded as an independent predictor of cardiovascular diseases plays a significant role in the development of ischemic heart disease. In patients with verified ischemic heart disease, hyperleptinemia causes hypertrophy of vascular smooth muscle cells, increases the synthesis of endothelial growth factor as well as the accumulation of reactive oxygen species in the vascular wall and leads to elevated expression of endothelin-1, which is also an indicator of its influence on vascular remodeling. Leptin is a predictor of a higher functional class of angina pectoris and heart rhythm disorders; it may be used as an indirect marker of systemic inflammation as well. Pathogenic basis for ischemic heart disease treatment is hypolipidemic therapy with statins as the medications of choice; in addition to basic hypolipidemic action, they improve endothelial function increasing nitric oxide synthesis possessing anti-inflammatory, anti-ischemic, antiaggregatory, antithrombotic and profibrinolytic action, as well as antioxidant and antiproliferative effects.The objective of the research was to study changes in blood lipids and leptin levels in patients with ischemic heart disease and concomitant non-alcoholic fatty liver disease after a course of atorvastatin. Materials and methods. 54 patients with ischemic heart disease and concomitant non-alcoholic fatty liver disease were examined; there were 26 individuals who did not take atorvastatin and 28 individuals taking atorvastatin at a dose of 40 mg per day for 3 months. All the patients underwent anthropometry, determination of blood lipids, leptin and liver transaminase levels, electrocardiography, echocardiography, ultrasound of the internal organs.Results. A significant decrease in the average level of total cholesterol (p<0.01), concentration of low-density lipoproteins (p<0.01) and leptin level (p<0.01) was detected in patients after 3 months of atorvastatin use. Moreover, there was detected a direct correlation between leptin level and triglyceride concentration, leptin level and the body mass index, leptin level and waist circumference, leptin level and hip circumference, as well as a high correlation between total cholesterol and low-density lipoproteins, and total cholesterol and the body mass index.Conclusions. The administration of atorvastatin to patients with ischemic heart disease and concomitant non-alcoholic fatty liver disease at a dose of 40 mg per day improves the patients’ general condition and promotes a significant decrease in the levels of pro-atherogenic fractions of blood lipids and leptin level, as well as promotes the reduction in risk factors for comorbid pathology and prevents the occurrence of its complications.

scholarly journals ISCHEMIC HEART DISEASE; ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE

2016 ◽  
Vol 23 (09) ◽  
pp. 1057-1059
Author(s):  
Dr. Zaigham Rasool Khalid ◽  
Dr. Naseem Ahmed ◽  
Dr. Farhan Ali Rizvi ◽  
Dr. Mirza Ahmad Raza Baig
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Disease Association ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals CLINICAL COURSE OF ISCHEMIC HEART DISEASE UNDER CONDITIONS OF COMORBIDITY WITH NON-ALCOHOLIC FATTY LIVER DISEASE.

2019 ◽  
Vol 19 (3) ◽  
pp. 52-56 ◽  
Author(s):  
Yu.I. Manusha ◽  
Yu.M. Kazakov ◽  
T.A. Trybrat ◽  
N.I Chekalina ◽  
K.Ye. Vakulenko
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Clinical Course ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Significant Difference ◽  
Alcoholic Fatty Liver Disease

The actual problem of modern medicine is the identification of common pathogenetic mechanisms of IHD and NAFLD in order to develop a complex, personalized approach in treatment and prevention of comorbid pathology. Aim of the study: to determine the clinical course peculiarities of ischemic heart disease under conditions of comorbidity with non-alcoholic fatty liver disease. The study involved 135 patients with ischemic heart disease: stable voltage angina, I-II FC, HF 0-1, combined with non-alcoholic fatty liver disease and 30 healthy individuals. At the first stage of the study an assessment of ischemic heart disease tendencies under circumstances of concomitant NAFLD was conducted taking into consideration the peculiarities of clinical symptoms, and in comparison groups there was no significant difference discovered eventually in cardiovascular systems complaints, which were caused by IHD development. In patients with IHD combined with NAFLD the incidence of myocardial bioelectric activity disorders and the frequency of rhythm disorders prevailed comparing to patients with IHD. A significant increase in total cholesterol and a blood atherogenic index was found in patients with IHD combined with NAFLD compared to the patients with IHD (p <0.05) in the analysis of lipidogram indices. No significant difference among other lipidogram indicators (LDL cholesterol, HDL cholesterol, TG) was observed (p> 0.05). Thus, the detected lipid metabolism disorders were noted in patients with IHD combined with NAFLD at statin therapy. Due to results of echocardiography a diastolic dysfunction and a moderate decrease of systolic function were found in both study groups comparing to the healthy group, regardless of the presence or absence of NAFLD. A higher incidence of LV hypertrophy was observed in patients with comorbid pathology.

scholarly journals Changes of carbohydrate and lipid metafbolism and c-reactive protein in patients with ischemic heart disease and fatty hepatose

2017 ◽  
Author(s):  
S. А. Tkachuk ◽  
H. V. Bashta ◽  
L. Ye. Lapovets ◽  
M. P. Zaletskyi
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Ischemic Heart ◽  
C Reactive Protein ◽  
Alcoholic Fatty Liver ◽  
Reactive Protein ◽  
Alcoholic Fatty Liver Disease

The aim of the study was to detect changes in lipid and carbohydrate metabolism and the level of C-reactive protein in patients with ischemic heart disease, combined with non-alcoholic fatty liver disease. Widespread ischemic heart disease combined with non-alcoholic fatty liver disease requires finding mutual pathogenetic mechanisms for improving the diagnosis and treatment optimization to improve the course and prognosis of these comorbid diseases. Patients with non-alcoholic fatty liver disease must be classified as high-risk population.

Sign in / Sign up

Export Citation Format

Share Document